A Phase 1 interventional study of OPC-167832 and Itraconazole in Healthy Volunteers, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 129 studies in Tuberculosis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Tuberculosis · United States.
Among the 129 studies in Tuberculosis with a site in United States, this one is the 69th largest by enrollment of the 94 interventional ones that give a count, is one of 4 that started in 2022, is one of 44 in phase 1, and was the 127th registered.
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
Browse Tuberculosis studies →4 of the 129 studies in Tuberculosis with a site in United States are open now. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 21+
Columbia University · Sites in United States
Ages 18+ · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mexico
Ages 18–99
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
129 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 13 · Phase 3 8 · Phase 4 8
First in 1992; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 150 across 820 interventional studies indexed under Tuberculosis.
Median enrollment 56 across the 94 interventional studies, 151 across the 32 observational. Of the 117 that completed or were terminated, 35 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 129 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 5 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Tuberculosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07737275Columbia UniversityScreening With Portable X-rays for Rapid Recognition of TB | 2027-05-25 |
Add it to your calendar (.ics) → With an account.
Among the 129 studies in Tuberculosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832. The study is conducted in 2 parts: Part 1 assesses the potential effect of the CYP3A inhibitor itraconazole on the metabolism of OPC-167832 and Part 2 assesses the potential effect of the CYP3A inducer carbamazepine on the metabolism of OPC-167832 in healthy adult participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In good health at screening as determined by:
Exclusion Criteria
Note: Other protocol-specified inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive single OPC-167832 dose, orally on Days 1 and 15, and itraconazole, orally, twice daily (BID), on Day 8 followed by itraconazole, once daily (QD) from Day 9 to Day 25 of Part 1.
Drug: OPC-167832 · Drug: Itraconazole
Participants receive single OPC-167832 dose, orally on Days 1 and 25, and carbamazepine Dose 1, orally, BID from Day 8 to Day 10, followed by Dose 2, BID from Day 11 to Day 13, and Dose 3, BID from Day 14 to Day 31 of Part 2.
Drug: OPC-167832 · Drug: Carbamazepine
Oral tablets.
Oral solution.
Oral tablets.
Part 1: Maximum Plasma Concentration (Cmax) of OPC-167832
Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.
Part 2: Cmax of OPC-167832
Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 168 hours postdose on Day 25.
Part 1: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of OPC-167832
Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.
Part 2: AUCt of OPC-167832
Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 168 hours postdose on Day 25.
Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinfinity) of OPC-167832
Time frame: Predose and up to 168 hours postdose on Day 1; and Predose and up to 264 hours postdose on Day 15.
Part 2: AUCinfinity of OPC-167832
Time frame: Predose and upto 168 hours postdose on Day 1; and Predose and upto 168 hours postdose on Day 25.
Parts 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a trial intervention and which does not necessarily have a causal relationship with this intervention. TEAEs are defined as AEs with an onset date on or after the start of IMP treatment.
Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters
Clinical laboratory tests for serum chemistry, hematology, and urinalysis were measured. Clinical significance was determined by the investigator.
Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Parts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities
Vital signs criteria for clinically significant changes: systolic blood pressure (greater than \[\>\]160 millimeters of mercury \[mmHg\] to less than \[\<\]90 mmHg), diastolic blood pressure (\>105 mmHg to \<50 mmHg), heart rate (\>110 beats per minute \[bpm\] to \<50 bpm), respiratory rate (\<12 breaths/min or \> 20 breaths/min), and temperature (\<36 degree Celsius \[°C\] or \>38°C).
Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Physical Examinations
The physical examination included height (screening only), weight, and calculation of body mass index (BMI), as well as assessment of the head, neck, eyes, ears, nose, and throat; thorax; abdomen; skin and mucosae; neurological; and extremities. Clinical significance was determined by the investigator.
Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Parts 1 and 2: Number of Participants With Potentially Clinically Relevant Changes in 12-lead Electrocardiogram (ECG) Parameters
Electrocardiogram measurements included heart rate (HR), PR, QRS, RR, QT, QTcF, QTcB). The participants were assessed based on the clinically relevant changes in ECG values as per criteria defined in SAP.
Time frame: Part 1: Up to 8 weeks; Part 2: Up to 9 weeks
Part 2: Number of Participants With Changes in Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.
Time frame: Up to 9 weeks
Participants took part in the study from 19 September 2022 to 11 December 2022.
| Milestone | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine |
|---|---|---|
| Started | 12 | 12 |
| Completed | 9 | 9 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 3 | 3 |
| nanograms per milliliter (ng/mL) | OPC-167832 | OPC-167832 and Itraconazole |
|---|---|---|
| Part 1: Maximum Plasma Concentration (Cmax) of OPC-167832 | 81.0 ± 29.3 | 144 ± 66.7 |
| ng/mL | OPC-167832 | OPC-167832 and Carbamazepine |
|---|---|---|
| Part 2: Cmax of OPC-167832 | 95.1 ± 36.6 | 95.8 ± 32.9 |
| Nanograms*hours per milliliter (ng*h/mL) | OPC-167832 | OPC-167832 and Itraconazole |
|---|---|---|
| Part 1: Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of OPC-167832 | 2310 ± 898 | 4490 ± 2390 |
| ng*h/mL | OPC-167832 | OPC-167832 and Carbamazepine |
|---|---|---|
| Part 2: AUCt of OPC-167832 | 2280 ± 808 | 1310 ± 345 |
| ng*h/mL | OPC-167832 | OPC-167832 and Itraconazole |
|---|---|---|
| Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinfinity) of OPC-167832 | 2180 ± 619 | 3660 ± 1170 |
| ng*h/mL | OPC-167832 | OPC-167832 and Carbamazepine |
|---|---|---|
| Part 2: AUCinfinity of OPC-167832 | 2330 ± 868 | 1350 ± 234 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant administered a trial intervention and which does not necessarily have a causal relationship with this intervention. TEAEs are defined as AEs with an onset date on or after the start of IMP treatment.
| Participants | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine |
|---|---|---|
| Parts 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 7 | 10 |
Clinical laboratory tests for serum chemistry, hematology, and urinalysis were measured. Clinical significance was determined by the investigator.
| Participants | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine |
|---|---|---|
| Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters | 0 | 0 |
Vital signs criteria for clinically significant changes: systolic blood pressure (greater than \[\>\]160 millimeters of mercury \[mmHg\] to less than \[\<\]90 mmHg), diastolic blood pressure (\>105 mmHg to \<50 mmHg), heart rate (\>110 beats per minute \[bpm\] to \<50 bpm), respiratory rate (\<12 breaths/min or \> 20 breaths/min), and temperature (\<36 degree Celsius \[°C\] or \>38°C).
| Participants | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine |
|---|---|---|
| Parts 1 and 2: Number of Participants With Clinically Significant Changes in Vital Signs Abnormalities | 0 | 0 |
The physical examination included height (screening only), weight, and calculation of body mass index (BMI), as well as assessment of the head, neck, eyes, ears, nose, and throat; thorax; abdomen; skin and mucosae; neurological; and extremities. Clinical significance was determined by the investigator.
| Participants | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine |
|---|---|---|
| Parts 1 and 2: Number of Participants With Potentially Clinically Significant Changes in Physical Examinations | 0 | 0 |
Electrocardiogram measurements included heart rate (HR), PR, QRS, RR, QT, QTcF, QTcB). The participants were assessed based on the clinically relevant changes in ECG values as per criteria defined in SAP.
| Participants | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine |
|---|---|---|
| Parts 1 and 2: Number of Participants With Potentially Clinically Relevant Changes in 12-lead Electrocardiogram (ECG) Parameters | 0 | 0 |
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.
| Participants | Part 2: OPC-167832 and Carbamazepine |
|---|---|
| Suicidal Behavior | 0 |
| Suicidal Ideation | 0 |
Collected over Part 1: Up to 8 weeks; Part 2: Up to 9 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: OPC-167832 and Itraconazole | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Part 2: OPC-167832 and Carbamazepine | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Event | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/12 | 1/12 |
| NauseaGastrointestinal disorders | 2/12 | 5/12 |
| HeadacheNervous system disorders | 3/12 | 5/12 |
| Vision BlurredEye disorders | 4/12 | 2/12 |
| DizzinessNervous system disorders | 3/12 | 3/12 |
| Abdominal PainGastrointestinal disorders | 2/12 | 1/12 |
| LymphadenopathyBlood and lymphatic system disorders | 0/12 | 2/12 |
| Non-cardiac Chest PainGeneral disorders | 0/12 | 2/12 |
| Disturbance in AttentionNervous system disorders | 0/12 | 2/12 |
| SomnolenceNervous system disorders | 0/12 | 2/12 |
The enrolled analysis dataset includes all participants that signed the informed consent form (ICF) and met all eligibility criteria.
| Age, Continuous(years) | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine | Total |
|---|---|---|---|
| Mean | 37.5 ± 11.1 | 39.8 ± 9.3 | 38.6 ± 10.1 |
| Sex: Female, Male(Participants) | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 7 | 8 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 12 | 9 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part 1: OPC-167832 and Itraconazole | Part 2: OPC-167832 and Carbamazepine | Total |
|---|---|---|---|
| White | 4 | 7 | 11 |
| Black or African American | 7 | 4 | 11 |
| Asian | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Ran from Sep 2022 to primary completion in Nov 2022, 1 month.
Results were first posted in Jun 2026, 3 years 6 months after primary completion.
Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's 1 month is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quabodepistat
Otsuka Pharmaceutical Development & Commercialization, Inc. →